Related Experiment Video
Updated: Dec 27, 2025
Quantification of Hypopigmentation Activity In Vitro
Published on: March 6, 2019
Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis
Kevin Phan1,2,3, Steven Phan1,2, Stephen Shumack3
1Department of Dermatology, Liverpool Hospital, Sydney, Australia.
Introduction:
Vitiligo is an autoimmune disorder characterized by progressive loss of melanocytes, leading to cutaneous depigmentation. Vitiligo has significant psychosocial impacts on patients and is challenging to manage with limited treatment options. Recent studies have suggested promising results for JAK1/3 inhibitors including tofacitinib and ruxolitinib.
Objective:
To determine the expected response of vitiligo to JAK inhibitor therapy and factors which influence response rates.
Methods:
A systematic review and meta-analysis was performed according to PRISMA guidelines. Good response was defined as repigmentation >50% or a 'good' or 'excellent' outcome as described by authors. Partial response was defined as some repigmentation <50%.
Results:
From the 9 eligible studies, individual patient data from 45 cases were pooled. Good response was achieved in 57.8%, partial response in 22.2%, and none or minimal response in 20% of cases. When subgrouped according to site, facial vitiligo had the highest good response rate (70%), compared to extremities (27.3%) and torso/non-sun exposed areas (13.6%). Concurrent phototherapy was significant associated with higher rates of good overall response (p < .001) and good facial response (p < .001).
Conclusions:
There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in vitiligo. Concurrent UVB phototherapy appears to improve efficacy of JAK inhibitors for vitiligo.
Insights
Janus kinase (JAK) inhibitors show promise for treating vitiligo, an autoimmune skin condition. Combining JAK inhibitors with UVB phototherapy may improve treatment effectiveness, especially for facial vitiligo.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Vitiligo is an autoimmune disorder causing melanocyte loss and skin depigmentation.
- It significantly impacts patients psychosocially and has limited treatment options.
- Janus kinase (JAK) inhibitors like tofacitinib and ruxolitinib show potential therapeutic benefits.
Purpose of the Study:
- To evaluate the efficacy of JAK inhibitors in treating vitiligo.
- To identify factors influencing response rates to JAK inhibitor therapy.
Main Methods:
- A systematic review and meta-analysis adhering to PRISMA guidelines.
- Defined good response as >50% repigmentation or 'good'/'excellent' outcome.
- Analyzed individual patient data from 45 cases across 9 studies.
Main Results:
- Good response to JAK inhibitors was observed in 57.8% of patients.
- Facial vitiligo showed the highest response rate (70%) compared to extremities (27.3%) and torso (13.6%).
- Concurrent UVB phototherapy significantly increased overall and facial response rates (p < .001).
Conclusions:
- JAK inhibitors demonstrate promising, though low-quality, evidence for vitiligo treatment.
- Combining JAK inhibitors with UVB phototherapy may enhance treatment efficacy for vitiligo.
Related Concept Videos
01:14Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
01:19Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
01:20The JAK-STAT Signaling Pathway
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...